Form 4: GoodRx Director Ian T. Clark Reports Significant Restricted Stock Unit Grant

GoodRx Holdings, Inc. Director Ian T. Clark has reported the acquisition of 57,050 Class A Common Stock shares through a restricted stock unit grant, increasing his direct beneficial ownership to 82,902 shares.

Summary

• Ian T. Clark, a Director of GoodRx Holdings, Inc. (GDRX), acquired 57,050 shares of Class A Common Stock on June 3, 2025.
• The acquisition was in the form of Restricted Stock Units (RSUs), with a transaction price of $0 per unit, indicating a grant rather than a purchase.
• Each RSU represents a contingent right to receive one share of Class A common stock.
• Following this transaction, Mr. Clark's direct beneficial ownership of Class A Common Stock increased to 82,902 shares.
• The RSUs are scheduled to vest in full on the earlier of (i) the one-year anniversary of June 3, 2025, and (ii) the date of the 2026 Annual Meeting of Stockholders, contingent upon Mr. Clark's continued service through the applicable vesting date.

Sentiment

Score: 7

Explanation: The grant of restricted stock units to a director is a positive sign of aligning management incentives with shareholder interests, though it's a routine compensation event rather than a strategic announcement that would significantly alter the company's fundamental outlook.

Positives

• The grant of restricted stock units to a director aligns their financial interests with those of long-term shareholders, encouraging decisions that enhance shareholder value.
• Equity compensation is a common and effective way to retain key talent and incentivize performance within a company's leadership.

Future Outlook

The document primarily details a past transaction and future vesting schedule for restricted stock units, rather than providing a general future outlook for the company's operations or financial performance.

Industry Context

The granting of restricted stock units to directors is a standard practice across various industries, including healthcare technology, to compensate board members and align their incentives with the company's long-term performance and shareholder interests.

Comparison to Industry Standards

• Granting equity compensation, such as Restricted Stock Units (RSUs), to non-employee directors is a widely adopted practice among publicly traded companies, including those in the technology and healthcare sectors like GoodRx.
• This method is favored for its ability to align the director's financial interests directly with the company's stock performance, similar to practices seen at companies like Teladoc Health (TDOC) or Amwell (AMWL) in the digital health space, or broader tech companies like Google (GOOGL) or Apple (AAPL) for their board compensation structures.
• The vesting schedule, tied to continued service and specific dates (one-year anniversary or next annual meeting), is also a common structure designed for retention and long-term commitment, consistent with corporate governance best practices.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Ian T. Clark, a director of GoodRx Holdings, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The RSU grant aligns the director's interests with shareholder value creation, as the value of the compensation is tied to the company's stock performance.
• Employees: While not directly impacting all employees, this type of compensation structure for leadership can set a precedent for equity-based incentives within the company.
• Director (Ian T. Clark): Receives equity compensation, incentivizing continued service and performance.

Next Steps

• The 57,050 restricted stock units will vest in full on the earlier of the one-year anniversary of June 3, 2025, or the date of the 2026 Annual Meeting of Stockholders, subject to continued service.

Key Dates

Keywords

GoodRx, GDRX, SEC Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Equity Grant, Beneficial Ownership